托法西提尼的自身免疫血液溶解性贫血在患有性结肠炎的患者中使用
Erin Zisman1, Rukaiya Bashir-Hamidu1, Lauren George1
1Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland Medical System, Baltimore, MD.
ACG case reports journal
|September 8, 2025
概括
托法西提尼布是一种Janus激酶抑制剂,很少会导致自身免疫性血清性贫血. 这一案例突出了一个患有炎症性肠道疾病的患者,在开始服用tofacitinib后,他患上了严重的贫血,需要输血.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 血液学 血液学 血液学
背景情况:
- 托法西提尼布是一种用于类风湿性关节炎和性结肠炎的Janus激酶抑制剂.
- 贫血是一种罕见的副作用,通常伴有轻微的血红蛋白变化.
- 自身免疫性溶血性贫血 (AIHA) 是一种严重但不常见的不良反应.
研究的目的:
- 报告第一个由托法西提尼布诱导的AIHA病例,发生在炎症性肠病 (IBD) 患者身上.
- 描述托法西提尼布诱导的AIHA的临床表现和管理.
主要方法:
- 一个患有IBD的患者的病例报告.
- 临床评估,包括对贫血的实验室检查.
- 用药物戒断,皮质类固醇和修复剂治疗.
主要成果:
- 患者在开始服用托法西提尼布后出现了输血依赖性贫血.
- 诊断工作证实了自身免疫血液溶解性贫血.
- 用类固醇和修复剂治疗导致血红蛋白稳定.
结论:
- 托法西提尼布可以诱导自身免疫血液溶解性贫血,即使在IBD患者中.
- 及时诊断和管理对于有利的结果至关重要.
- 这一案例强调了监测JAK抑制剂罕见不良反应的重要性.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
506
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
506
Drugs for Treatment of Ulcerative Colitis in IBD
463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
495
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
495
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439
Inflammatory Bowel Disease I: Ulcerative Colitis
904
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
904
Inflammatory Bowel Disease IV: Pharmacological Management
531
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
531


